Studien | Der Arzneimittelbrief

ARISTOTLE Studie

Apixaban for Reduction In STroke and Other ThromboemboLic Events in atrial fibrillation trial

Literaturstellen

Arch.Intern.Med. 2007,167,1655
Am.Heart J. 2010,159,331; 1162; 2013,166,549; 559; 2014,168,303; 2017,185,140; 2023,265,132
N.Engl.J.Med. 2011,365,981; 2012,366,89; 2017,377,2133; 2018,379,1224
Lancet 2012,380,1749; 2013,381,204
Lancet Neurol. 2012,11,503
Eur.Heart J. 2012,33,2821; 2013,34,2464; 2014,35,224; 1864
Int.J.Cardiol. 2013,170,215
J.Am.Coll.Cardiol. 2013,61,2274; 2014,63,52; 1082; 2141; 2014,64,1541; 1551; 2018,71,1; 2018,72,721
J.Thromb.Thrombolysis 2014,38,150; 2018,46,316
Circulation 2013,127,2166; 2014,129,625; 2014,130,1847; 2015,132,624; 2016,134,1697; 2018,72,721; 2019,139,2292
Circ.Heart Fail. 2013,6,451
Cardiovasc.Ther. 2014,32,214
J 2016,353,i2868
J.Am.Heart Assoc. 2017,6,e004699; 2018,7,e007444
A Cardiol. 2017,2,525
Am.J.Med. 2018,131,269
J.Am.Coll.Cardiol. 2018,71,1063
Clin.Cardiol. 2019,42,568
Am.Heart J. 2022,251,13; 2023,265,132
Open Heart 2025,12,e002966